The HemoSonic monitor (HemoSonic 100™, Arrow International, Reading, PA, U.S.A.) is a minimally invasive device to determine cardiac output by means of M-mode and pulsed Doppler ultrasound. We evaluated the HemoSonic monitor by comparing its output to paired measurements obtained by the standard thermodilution technique in patients who had recently undergone cardiac surgery. Forty-seven paired measurements were carried out in 13 patients. The correlation between the two methods was very good with a correlation coefficient of 0.81. Comparison of the two techniques using the method described by Bland and Altman showed a mean of the differences of -0.23. The limits of agreement were -2.35 to 1.89. There was a reduced correlation between techniques at higher values of cardiac output.
A reliable method of non-invasive or minimally invasive cardiac output measurement has potential applications in the Intensive Care Unit (ICU), but has been somewhat elusive.
The HemoSonic cardiac output monitor (HemoSonic 100™, Arrow International, Reading, PA, U.S.A.) has recently become commercially available for use in critically ill patients. The HemoSonic monitor comprises a 7 mm diameter oesophageal probe incorporating both M-mode and pulsed Doppler ultrasound transducers. The cardiac output is determined from a known correlation between aortic blood flow and cardiac output. The M-mode is used to measure the diameter of the descending aorta and the pulsed Doppler is used to measure the velocity of blood travelling down the descending aorta for each cardiac cycle. The use of an oesophageal Doppler probe was first described by Side and Gosling in 1971 1 . The first commercial Doppler device within an oesophageal probe was described by Mark and co-workers in 1986 (Ultracom Medical Systems, Seattle, WA, U.S.A.) 2 .
The aim of this study was to evaluate the HemoSonic monitor against the thermodilution technique of cardiac output measurement in patients in the ICU who had recently undergone cardiac surgery.
MATERIALS AND METHODS
Forty-seven paired measurements of cardiac output were carried out on 13 cardiac surgery patients on their return from the operating room. Institutional ethics approval was obtained for the conduct of the trial. Written informed consent was obtained from subjects on the night prior to surgery for enrolment in the trial and for insertion of the HemoSonic probe into the oesophagus.
The HemoSonic monitor probe was inserted on admission to the ICU as prescribed by the manufacturer. Standard thermodilution cardiac output measurements were carried out via pulmonary artery catheters (7.5 gauge Arrow, Arrow International, Reading, PA, U.S.A.) on these patients as clinically indicated. The pulmonary artery catheters had been placed in the operating room as part of the standard management of patients undergoing cardiac surgery. Thermodilution cardiac output was measured using three 10 millilitre bolus injections of 5% dextrose water at a temperature of approximately 4°C. The averaged values for the three results were used to determine each cardiac output.
The HemoSonic monitor provided updated cardiac output values continuously once correctly sited in the oesophagus (Figure 1 ). Every time a thermodilution cardiac output measurement was taken, the most recent HemoSonic measurement (immediately prior to the thermodilution measurement) was also recorded. Paired measurement recording was ceased when the patient was ready for weaning from mechanical ventilation.
The paired values were recorded manually on a work sheet. The correlation coefficient for the two methods was calculated. In addition a plot of the differences between the methods against their mean was 409 HEMOSONIC MONITOR IN carried out according to the method of Bland and Altman 3 .
RESULTS
Forty-seven paired measurements from 13 patients were recorded. The cardiac output values for each of the 13 patients for both methods are shown graphically in Figure 2 . The correlation coefficient (Pearson correlation, two-tailed) was 0.81, significant at the 0.01 level.
The mean (95% confidence interval in brackets) of the differences (estimate of bias) between the two techniques was -0.23 (-0.54 to 0.08), with a standard deviation of 1.06 and a standard error of 0.154. The limits of agreement (95% confidence interval in brackets) for the two techniques was -2.35 (-2.62 to -2.08) to 1.89 (1.62 to 2.16). The Bland-Altman plot (Figure 3 ) also showed that as cardiac output increased, so the difference between the two methods also increased.
Insertion of the oesophageal probe was uncomplicated, except for one case of tracheal placement (despite the presence of an endotracheal tube). This was immediately recognised and corrected.
DISCUSSION
Cardiac output as determined by the HemoSonic monitor correlated well with that determined by thermodilution in this group of post cardiac surgery patients. These findings are in keeping with previous published work 4 . Graphically (Figures 2 and 3) it appears the correlation between the two methods was better in the physiological cardiac output range and less so at higher cardiac outputs.
The HemoSonic monitor has the advantage of being a minimally invasive method of measuring cardiac output with real-time display of data. As such, it has application in patients where pulmonary artery catheterization is not possible or desirable. It avoids all the potential complications of pulmonary artery catheter insertion and maintenance. It does however require insertion of a probe into the oesophagus, a procedure not well tolerated by awake patients. This limits the application of the HemoSonic monitor to patients who are sedated or anaesthetized. In addition the correct positioning of the oesophageal probe is crucial to the accuracy of the monitor. This takes some instruction and there is an associated learning curve. All the measurements in our study were performed by the same person (DM) to avoid operator-induced interference in the study. The cost of the HemoSonic consumables is considerable, but at $200 to $300 per application is comparable to the cost of placing and maintaining a pulmonary artery catheter. We concluded that the HemoSonic monitor has a place in intensive care monitoring. Its main advantages are its accuracy and the continuous nature of its readout. The correlation with cardiac output as measured by thermodilution in post cardiac surgery patients was good. However, the bias was -0.23 l/min, with 95% limits of agreement of -2.35 to +1.89 l/min.
